Cargando…

Anti-spike antibody response to the COVID vaccine in lymphoma patients

Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Della Pia, Alexandra, Kim, Gee Youn (Geeny), Ip, Andrew, Ahn, Jaeil, Liu, Yanzhi, Kats, Simone, Koropsak, Michael, Lukasik, Brittany, Contractor, Anamta, Amin, Krushna, Ayyagari, Lakshmi, Zhao, Charles, Gupta, Amolika, Batistick, Mark, Leslie, Lori A., Goy, Andre H., Feldman, Tatyana A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714943/
https://www.ncbi.nlm.nih.gov/pubmed/36454941
http://dx.doi.org/10.1371/journal.pone.0266584
_version_ 1784842348429049856
author Della Pia, Alexandra
Kim, Gee Youn (Geeny)
Ip, Andrew
Ahn, Jaeil
Liu, Yanzhi
Kats, Simone
Koropsak, Michael
Lukasik, Brittany
Contractor, Anamta
Amin, Krushna
Ayyagari, Lakshmi
Zhao, Charles
Gupta, Amolika
Batistick, Mark
Leslie, Lori A.
Goy, Andre H.
Feldman, Tatyana A.
author_facet Della Pia, Alexandra
Kim, Gee Youn (Geeny)
Ip, Andrew
Ahn, Jaeil
Liu, Yanzhi
Kats, Simone
Koropsak, Michael
Lukasik, Brittany
Contractor, Anamta
Amin, Krushna
Ayyagari, Lakshmi
Zhao, Charles
Gupta, Amolika
Batistick, Mark
Leslie, Lori A.
Goy, Andre H.
Feldman, Tatyana A.
author_sort Della Pia, Alexandra
collection PubMed
description Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody level following the primary COVID vaccination series. The primary vaccination series was defined as 2 doses of the COVID mRNA vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher’s exact test, and unadjusted and adjusted logistic regression models were used for univariate and multivariate analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 patients (23%) with Burkitt’s, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL); 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined; 12 patients (5%) with mantle cell lymphoma; and 4 patients (2%) with other lymphoma types. One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a numerically lower seroconversion rate of 51% following the primary vaccination series whereas patients with HL/TCL appeared to have a robust antibody response with a seropositivity rate of 77% (p = 0.04). Lymphoma patients are capable of mounting a humoral response to the COVID vaccines. Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical relevance in this patient population.
format Online
Article
Text
id pubmed-9714943
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-97149432022-12-02 Anti-spike antibody response to the COVID vaccine in lymphoma patients Della Pia, Alexandra Kim, Gee Youn (Geeny) Ip, Andrew Ahn, Jaeil Liu, Yanzhi Kats, Simone Koropsak, Michael Lukasik, Brittany Contractor, Anamta Amin, Krushna Ayyagari, Lakshmi Zhao, Charles Gupta, Amolika Batistick, Mark Leslie, Lori A. Goy, Andre H. Feldman, Tatyana A. PLoS One Research Article Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody level following the primary COVID vaccination series. The primary vaccination series was defined as 2 doses of the COVID mRNA vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher’s exact test, and unadjusted and adjusted logistic regression models were used for univariate and multivariate analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 patients (23%) with Burkitt’s, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL); 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined; 12 patients (5%) with mantle cell lymphoma; and 4 patients (2%) with other lymphoma types. One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a numerically lower seroconversion rate of 51% following the primary vaccination series whereas patients with HL/TCL appeared to have a robust antibody response with a seropositivity rate of 77% (p = 0.04). Lymphoma patients are capable of mounting a humoral response to the COVID vaccines. Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical relevance in this patient population. Public Library of Science 2022-12-01 /pmc/articles/PMC9714943/ /pubmed/36454941 http://dx.doi.org/10.1371/journal.pone.0266584 Text en © 2022 Della Pia et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Della Pia, Alexandra
Kim, Gee Youn (Geeny)
Ip, Andrew
Ahn, Jaeil
Liu, Yanzhi
Kats, Simone
Koropsak, Michael
Lukasik, Brittany
Contractor, Anamta
Amin, Krushna
Ayyagari, Lakshmi
Zhao, Charles
Gupta, Amolika
Batistick, Mark
Leslie, Lori A.
Goy, Andre H.
Feldman, Tatyana A.
Anti-spike antibody response to the COVID vaccine in lymphoma patients
title Anti-spike antibody response to the COVID vaccine in lymphoma patients
title_full Anti-spike antibody response to the COVID vaccine in lymphoma patients
title_fullStr Anti-spike antibody response to the COVID vaccine in lymphoma patients
title_full_unstemmed Anti-spike antibody response to the COVID vaccine in lymphoma patients
title_short Anti-spike antibody response to the COVID vaccine in lymphoma patients
title_sort anti-spike antibody response to the covid vaccine in lymphoma patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714943/
https://www.ncbi.nlm.nih.gov/pubmed/36454941
http://dx.doi.org/10.1371/journal.pone.0266584
work_keys_str_mv AT dellapiaalexandra antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT kimgeeyoungeeny antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT ipandrew antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT ahnjaeil antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT liuyanzhi antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT katssimone antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT koropsakmichael antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT lukasikbrittany antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT contractoranamta antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT aminkrushna antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT ayyagarilakshmi antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT zhaocharles antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT guptaamolika antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT batistickmark antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT leslieloria antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT goyandreh antispikeantibodyresponsetothecovidvaccineinlymphomapatients
AT feldmantatyanaa antispikeantibodyresponsetothecovidvaccineinlymphomapatients